These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30402450)

  • 21. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.
    Grint D; Peters L; Rockstroh JK; Rakmanova A; Trofimova T; Lacombe K; Karpov I; Galli M; Domingo P; Kirk O; Lundgren JD; Mocroft A;
    AIDS; 2015 Jun; 29(10):1205-15. PubMed ID: 25870984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals.
    Noureddin M; Wong MM; Todo T; Lu SC; Sanyal AJ; Mena EA
    World J Gastroenterol; 2018 Mar; 24(11):1269-1277. PubMed ID: 29568207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Hsu SJ; Chen CL; Hwang JJ; Lai MY; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2010 May; 25(5):970-7. PubMed ID: 20546452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C.
    Lorenzo-Zúñiga V; Bartolí R; Masnou H; Montoliu S; Morillas RM; Planas R
    Dig Dis Sci; 2007 Nov; 52(11):3245-50. PubMed ID: 17410466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
    Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury.
    Lecube A; Hernández C; Genescà J; Esteban JI; Jardí R; Simó R
    Diabetes Care; 2004 May; 27(5):1171-5. PubMed ID: 15111540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
    Chen YC; Chang TS; Chen CH; Cheng PN; Lo CC; Mo LR; Chen CT; Huang CF; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Dai CY; Kao JH; Chuang WL; Lin HC; Chen CY; Tseng KC; Yu ML; On Behalf Of Tacr Investigators
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver stiffness improvement in hepatitis C patients after successful treatment.
    Brakenhoff SM; Verburgh ML; Willemse SB; Baak LC; Brinkman K; van der Valk M
    Neth J Med; 2020 Dec; 78(6):368-375. PubMed ID: 33380534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C Virus Clearance with Glucose Improvement and Factors Affecting the Glucose Control in Chronic Hepatitis C Patients.
    Yuan M; Zhou J; Du L; Yan L; Tang H
    Sci Rep; 2020 Feb; 10(1):1976. PubMed ID: 32029793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment.
    Stasi C; Sadalla S; Carradori E; Monti M; Petraccia L; Madia F; Gragnani L; Zignego AL
    Curr Med Res Opin; 2020 Feb; 36(2):245-249. PubMed ID: 31702411
    [No Abstract]   [Full Text] [Related]  

  • 39. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.